uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases06240uPAR-targeting human VH antibodies offer potent, versatile cancer and fibrotic-disease therapy with VH-Fc formats.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - mAbTherapeutic AreasHepatologyOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaGastric Cancer / Intestinal AdenocarcinomaMelanomaLead InventorDimiter DimitrovAll Tech InnovatorsXiaojie ChuDimiter Stanchev DimitrovWei LiTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2022-12-06CollectionsCardiometabolicWomen's & Reproductive Health
Novel Senotherapeutic Agents for Cancer Therapy06267Senotherapeutic sGC activator cinaciguat induces apoptosis in senescent prostate cancer cells, reducing recurrence and BPH progression.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasUrologyOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsAgingLead InventorAnthony KanaiDepartmentMed-MedicineAll Tech InnovatorsYouko IkedaAnthony J. KanaiIrina Valerjevna ZabbarovaTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-01-12
Fusion Gene-Based Machine Learning Tool Enhances Prediction of Prostate Cancer Clinical Outcomes06089Fusion-gene based machine learning boosts prostate cancer recurrence predictions using 14 gene signatures across multiple cohorts.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasUrologyOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsGeneticsLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsShuchang LiuJianhua LuoGeorge MichalopoulosDate Submitted2022-07-01
Fully Human Antibodies Targeting Membrane Proximal Region in Human CEACAM505469Fully human CEACAM5-targeting antibody binds membrane-proximal region with high specificity, enabling CAR-T/biotherapeutic cancer therapy.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - mAbTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsImmuno-oncologyLead InventorDimiter DimitrovAll Tech InnovatorsDusan BaekDimiter Stanchev DimitrovJohn W. MellorsTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2020-08-06
A Novel Treatment for Metastatic Prostate Cancer06044Novel allosteric AR modulators found to disrupt AR-TIF2 signaling, offering potential treatment for metastatic castration-resistant prostate cancer.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorPaul JohnstonDepartmentPharm-Pharmaceutical ScienceAll Tech InnovatorsCarlos Jaime CamachoAndrew P. HinckPaul A. JohnstonTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2022-06-01
PSMA with Multiple Single-Chain and Domain Binders Treats Prostate Cancer05717PSMA-targeting small VH-domain antibodies enable potent ADC/ADCC/CAR-T therapies with enhanced tumor penetration and distinct epitopes.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - mAbTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsImmuno-oncologyLead InventorDimiter DimitrovAll Tech InnovatorsDimiter Stanchev DimitrovDontcho V. JelevWei LiTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2021-06-09
Advanced Methods for Diagnosing Prostate Cancer and Predicting Relapse02406CNV-based genome analysis predicts prostate cancer progression and relapse, enabling personalized diagnostics and targeted treatment planning.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsPrecision medicineClinical Decision SupportLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsJianhua LuoGeorge MichalopoulosJoel B. NelsonTechnology Readiness Level5. Analytical validationDate Submitted2011-02-15
Wearable Acoustic System for Real-Time Prediction and Prevention of Bone Fractures07401Wearable acoustic sensors predict bone fractures by analyzing micro-crack sounds, enabling early warnings and noninvasive monitoring.Technology TypeMedical DeviceTechnology SubtypeMonitoring Medical DeviceTherapeutic AreasMusculoskeletalOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaOsteoporosisTagsPersonalized MedicineLead InventorAndrew BungerDepartmentCivil & Environmental EngineeringAll Tech InnovatorsAndrew P. BungerLan Gardner CoffmanCharles Clemenes HagerTechnology Readiness Level5. Advanced prototype validationDate Submitted2025-11-04CollectionsRegenerative MedicineWomen's & Reproductive Health
Identification of Fully Human anti-PSCA Antibodies05676Fully human anti-PSCA antibodies enable targeted therapy and ADCs for PSCA-expressing prostate and other solid tumors.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - FabTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaPancreatic adenocarcinomaRenal cell carcinoma (RCC)Lead InventorDimiter DimitrovAll Tech InnovatorsDusan BaekDimiter Stanchev DimitrovDontcho V. JelevTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2021-04-21
Instrument-Free Assay for In-Clinic Detection of Bladder or Prostate Cancer03825Colorimetric, instrument-free urine test detects bladder/prostate cancer via MMP-2/9–triggered Fe(II) release and Fenton reaction.Technology TypeDiagnostic/AssayTechnology SubtypeOther Diagnostic/AssayTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorAbhinav AcharyaDepartmentChem/Petroleum EngineeringAll Tech InnovatorsAbhinav Prakash AcharyaSteven R. LittleTatum Varut TarinDate Submitted2016-02-09
EAF1 and EAF2 Mouse Monoclonal Antibodies02877Novel EAF1/EAF2 mouse antibodies enable specific WB, IHC, ELISA, and IP use for transcription factors and cancer research.Technology TypeLife Science Research ToolTechnology SubtypeProteinTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorXinhui WangDepartmentMed-ImmunologyAll Tech InnovatorsJunkui AiSoldano FerroneXinhui Wang MD, PhDDate Submitted2012-08-29CollectionsHealthcare AI
Fully Human FAbs to IGF-1 and IGF-204929Fully human IGF-1/IGF-2–binding Fabs block IGF signaling to curb cancer cell growth, offering novel therapeutics.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - FabTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaColorectal cancer (CRC)Ductal carcinoma (Breast cancer)Lead InventorDimiter DimitrovAll Tech InnovatorsDusan BaekDimiter Stanchev DimitrovJohn W. MellorsTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2019-03-24CollectionsWomen's & Reproductive Health
Human Antibody Domains and Fragments to CD27606094Fully human single-domain antibodies and fragments target CD276 (B7-H3), enhancing tumor penetration and potential immune checkpoint blockade.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - mAbTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaMelanomaGlioblastomaLead InventorDimiter DimitrovAll Tech InnovatorsDimiter Stanchev DimitrovDontcho V. JelevJohn W. MellorsTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2022-07-06
Novel Targeted Gene Therapy for Cancers06452Targeted HSV1-tk genome editing at cancer fusion breakpoints to induce tumor cell death, offering genotype-specific therapy potential.Technology TypeTherapeutic ModalityTechnology SubtypeGene Therapy - CRISPRTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaHepatocellular carcinoma (HCC)Lead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsMuhamuda KaderShuchang LiuJianhua LuoTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2023-07-06CollectionsCell & Gene Therapy
PNA-Linked Electrochemical Biosensor Platform for Quantitative Analyte Detection01548A modular PNA-linked biosensor enables fast, highly sensitive electrochemical PSA detection with ready-made point-of-care applications.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorJoanne YehDepartmentMed-Structural BiologyAll Tech InnovatorsJoanne I-Ti YehDate Submitted2007-08-09
Innovative Leukocyte Genomic CNV Analysis for Predicting Prostate Cancer Outcomes03651Leukocyte CNV profiling predicts prostate cancer outcomes; improves recurrence risk estimates when combined with Gleason, Nomogram, and fusion status.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaLead InventorJianhua LuoDepartmentMed-PathologyAll Tech InnovatorsShuchang LiuJianhua LuoGeorge MichalopoulosDate Submitted2015-06-16
Diagnostic Test and Drug Development for Benign Prostatic Hyperplasia02090Discovery of BPH-V retrovirus linked to hypomethylation; enables targeted diagnostics, antivirals, vaccines, and personalized BPH therapy.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasOncologyUrologyTherapeutic IndicationsProstate cancer / adenocarcinomaOtherLead InventorDenise O'KeefeDepartmentMed-UrologyAll Tech InnovatorsDenise Susan O'KeefeDate Submitted2009-10-13
Non-Steroidal Androgen Receptor Antagonists for Advanced Prostate Cancer Therapy02501Non-steroidal androgen receptor antagonists deliver potent, resistance-guarded therapy for metastatic prostate cancer with favorable safety and PK.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTherapeutic IndicationsProstate cancer / adenocarcinomaTagsPrecision medicineLead InventorZhou WangDepartmentMed-UrologyAll Tech InnovatorsPaul A. JohnstonJohn S. LazoJoel B. NelsonTechnology Readiness Level4. Pre-clinical developmentDate Submitted2011-06-10
